The UK National Screening Committee (NSC) had recently held a consultation reviewing the evidence for whether to screen new-born babies for cytomegalovirus (CMV). Screening does not currently take place in the UK and the consultation called for new evidence which the Committee could use to consider a change in this policy.
Unfortunately there is no substantial evidence which is likely to change the committee’s recommendation not to screen and CMV Action does recognise that not all criteria for screening have been met. However, CMV Action prepared a number of responses to the consultation (working with a consortium of eminent medics working in the CMV field who also submitted a response), pointing out that CMV is a significant public health burden in the UK and that there are a number of practical steps that can be taken to reduce its impact whilst research is underway to address evidence gaps. We also called for discussions about how research could be prioritised in the UK to advance specific details of how universal new-born screening for congenital CMV could be carried out effectively.
We now await the results of the review which are expected to be completed by December 2017.